Shares of Amgen, Inc. (NASDAQ:AMGN) ended Thursday session in green amid volatile trading. The shares closed up +0.07 points or 0.04% at $170.13 with 1.88 million shares getting traded. Post opening the session at $170.55, the shares hit an intraday low of $168.62 and an intraday high of $170.56 and the price vacillated in this range throughout the day. The company has a market cap of $126.80 billion and the numbers of outstanding shares have been calculated to be 748.36 million shares.
Amgen, Inc. (AMGN) on Sept. 1, 2016 announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials.
The approval is based on results from the Phase 1/2 ‘205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL.
Shares of StemCells Inc (NASDAQ:STEM) ended Thursday session in red amid volatile trading. The shares closed down -0.05 points or -3.14% at $1.54 with 501,836.00 shares getting traded. Post opening the session at $1.60, the shares hit an intraday low of $1.51 and an intraday high of $1.60 and the price vacillated in this range throughout the day. The company has a market cap of $18.75 million and the numbers of outstanding shares have been calculated to be 12.01 million shares.
StemCells Inc (STEM) on Aug. 16, 2016 announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions.
“This transaction concludes an extensive search for strategic alternatives conducted by StemCells since we failed to see robust clinical results in our Phase II clinical study of human neural stem cells in chronic spinal cord injury,” said Ian Massey, the CEO of StemCells, Inc. “We believe both our investors and the market at large will see the potential of Microbot’s robotics platform, specifically its catheter and shunt technologies, and will appreciate Microbot’s overall business opportunities and potential.”
Harel Gadot, the CEO & Chairman of Microbot added, “We are pleased that this transaction will give us a presence in the U.S. capital markets, and we are very excited to continue advancing the development of our proprietary technologies that we believe have the potential to improve the lives of many patients globally. We thank StemCells for its efforts and contributions to improving human health over the years.”